S
hort-term treatment with swallowed topical corticosteroids (STCs) has proven efficacy in inducing clinical, endoscopic, and histologic remission in adult patients with eosinophilic esophagitis (EoE) and has been recently approved by the European Medicines Agency. [1] [2] [3] In contrast, data on long-term maintenance treatment are sparse. To date, one randomized controlled trial that included 28 adult patients has been conducted that evaluated 1-year remission rates only. 4 Beyond the time frame of 1 year, the impact of STC treatment on disease course in adults with EoE has not been rigorously studied. In the observational study by Kuchen et al, 5 long-term use of STCs was associated with a reduced risk of long-lasting food impactions. By using data from the same population, our group has shown that deep remission, which we defined as clinical, endoscopic, and histologic remission for at least 6 months, was achieved by 9% of the patients. 6 Almost all of these patients experienced symptomatic relapse after discontinuation of STCs. More than 90% needed long-term therapeutic management and displayed some degree of disease activity when treated with a low dose of 0.5 mg STC per day. 6 Nevertheless, we showed that patients benefit from ongoing STC treatment, with slightly increasing deep remission rates and a reduced risk of long-lasting food impactions over time. 5, 6 In spite of these recent findings, the general course of EoE under long-term STC management has not been well-explored, and a comprehensive picture of STC maintenance treatment is still missing. It has yet to be determined whether patients clearly benefit from long-term treatment with regard to the rates of clinical, endoscopic, and histologic remission.
Potential side effects of corticosteroids are a matter of concern for patients undergoing long-term treatment. Short-term STC trials have shown that Candida albicans infections occur with a frequency of up to 22%, but the risk of infections associated with lower maintenance doses has not been rigorously assessed. 1, 2, 4, 6 In addition, it is well-established that topical application of corticosteroids to the skin results in epithelial atrophy and disruption of epithelial integrity. 7, 8 Because the skin and the esophagus share many similarities regarding their histomorphologic structure, this potential side effect requires careful exploration. The data on safety of STC use in 33 patients analyzed in our previous study are of some value, but larger studies are needed to assess these safety concerns. 6 The purposes of this study were elucidation of the effectiveness as well as assessment of the safety profile of long-term use of STC in adult EoE patients.
Methods

Study Design
In this single-center observational study, we retrospectively evaluated a cohort of EoE patients who received an induction treatment with STC 1.0 mg twice a day (2-4 weeks until clinical response), followed by an infinite maintenance treatment of 0.25 mg twice a day according to our previously published therapeutic concept (Supplementary Methods). 6 This concept has been rigorously applied to all our patients since 2007. Disease activity was assessed clinically, endoscopically, and histologically on annual basis regardless of presence or absence of EoE symptoms. All patients were seen by a single EoE expert (A.S.). Patients had provided written informed consent before inclusion into the Swiss EoE database (SEED). The study was approved by the local ethics committee (EKNZ 2015-388).
Patients and Data Collection
Set up in 1989, SEED is a nation-wide database of patients with confirmed EoE diagnosis established in accordance with defined criteria. 9 At the time of study analysis, the SEED contained data on 783 EoE patients. Inclusion criteria for the SEED have been published elsewhere. 6 For the purpose of this study, the following inclusion criteria were applied: (1) patients underwent baseline examination and !1 follow-up examinations (!1 year) with standardized assessment of symptoms, endoscopic, and histologic findings; (2) patients showed clinical response to STC induction treatment within 2-4 weeks; (3) patients were treated with a maintenance regimen (0.25 mg twice a day) after induction of clinical response; and (4) the documentation related to the effectiveness of this treatment regimen was available. Patients who followed food elimination diet were excluded from analysis. All documents were reviewed, and data were extracted from patients' records by one physician (T.G.) under the close supervision of EoE experts (A.S., A.M.S.). Endoscopic disease activity was graded by using an EoE Endoscopic Reference Score (EREFS) grading and classification system based on the available endoscopic pictures. 10 This EREFS-based score ranges from 0 to 8 by assigning the values of 1 and 2 to mild and severe exudates; 1, 2, and 3 to mild, moderate, and severe rings; 1 to edema; 1 to furrows; and 1 to strictures. Absence of these features was scored with 0. For endoscopic pictures taken before 2012, images were re-assessed in retrospect to assign an EREFS score.
What You Need to Know
Background Data on long-term management of eosinophilic esophagitis (EoE) with swallowed topical corticosteroids are limited.
Findings
Swallowed topical corticosteroids are more effective than no treatment in the long-term management of EoE. Maintenance remission proportions are lower than those seen after short-term induction treatment. Nonetheless, longer duration of steroid treatment and higher cumulative doses are associated with higher proportions of complete remission compared with shorter duration and lower doses. An applied dose of 0.25 mg twice daily is safe and well-tolerated.
Implications for patient care
Indefinite long-term EoE treatment with swallowed topical corticosteroids should be considered. Because patients rarely achieve complete remission with the steroid doses used for the purposes of their clinical care, prospective long-term trials comparing different doses are needed in the future.
Definitions Used in This Study
For the purpose of this study, the following definitions were used: -Clinical remission: absence of any EoE-attributed symptoms, 9 in particular dysphagia, retrosternal pain, and heartburn, in patients with unrestricted nutritional habits; -Endoscopic remission: no endoscopic signs of inflammation detectable, in particular white exudates, furrows, and edema, 10 mild rings may be present; -Histologic remission: peak eosinophil count < 15 eosinophils/high-power field (hpf); -Complete remission: combination of clinical, endoscopic, and histologic remission.
-Number of days under STC: consecutive days of STC treatment at the time of follow-up visit.
-Cumulative doses of STC: multiples of 0.25 mg STC that were cumulatively taken until the time of followup visit.
Study Endpoints
As primary endpoint, we determined the proportions of clinical, endoscopic, and histologic remission in all patients and in patient groups stratified on the basis of the status and duration of STC treatment. As secondary endpoints, we examined (1) factors associated with attainment of remission, (2) factors associated with presence of symptoms despite endoscopic and histologic remission, (3) the relationship between clinical, endoscopic, histologic, and laboratory findings, and (4) STC side effects.
Statistical Analysis
For all statistical analyses, IBM SPSS software (version 22.0.0; 2013 SPSS Science, Chicago, IL) was used. Briefly, categorical data were compared by using c 2 test; differences in quantitative data distributions were assessed by using the unpaired Student t test and the Mann-Whitney-Wilcoxon test; multivariate logistic regression was performed by taking into account all covariates with a univariate P value <.1 (Supplementary Methods). For the purpose of this study, a P value <.05 was considered statistically significant.
Results
Patient and Disease Characteristics at Baseline and Follow-up Visits
Of a total of 783 eligible patients enrolled in the SEED, 229 were included in this analysis (175 men; mean age at diagnosis, 39 AE 15 years; median diagnostic delay, 6 years, interquartile range [IQR], 2-13; Table 1 ). Figure 1 depicts the flowchart for patients`selection in this study as well as missing data. In total, 819 follow-up visits (median of 3 visits, IQR, 2-5; median follow-up time of 5 years, IQR, 3-7) were analyzed ( Table 1) . Median time between follow-up visits was 11 months (IQR, 3-20).
Remission During Follow-up Visits
The remission proportions for all visits are shown in Table 2 ).
Treatment With Swallowed Topical Corticosteroids
During 336/819 visits (41.0%; 2.1 years [IQR, 0.8-4.5] after enrollment), patients were undergoing treatment with STC, whereas during 468 visits (57.1%; 1.7 years [IQR, 0.7-4.1] after enrollment), patients were without any treatment. For 15 visits, intake of STC could not be clearly verified (1.8%). When we compared visits with STC treatment and those without STC, no differences with regard to gender and disease characteristics, such as age at diagnosis, disease onset, and diagnostic delay, were observed. At visits under STC treatment, median peak eosinophil counts (5 vs 40/hpf; P < .001) and EREFS-based score (2.0 vs 4.0, P < .001) were lower than at visits without such treatment. At visits when patients were treated with STC, clinical (31.0% vs 4.5%, P < .001), endoscopic (48.8% vs 17.8%, P < .001), histologic (44.8% vs 10.1%, P < .001), and complete remission (16.1% vs 1.3%, P < .001) was more likely to be observed compared with visits when patients were not under STC treatment ( Figure 2 ). If patients had received endoscopic dilation within 1 year before the visit, the difference regarding clinical remission between STC-treated and non-treated patients was less pronounced (Supplementary Figure 1) . When analyzing remission proportions per patient after 3 follow-up visits (corresponding to the median number of follow-up visits), these proportions were higher for patients treated with STC compared with those without treatment: 32.2% vs 6.6% (clinical remission, P < .001), 45.8% vs 23.7% (endoscopic remission, P ¼ .007), 49.2% vs 9.2% (histologic remission, P < .001), and 16.9% vs 2.6% (complete remission, P ¼ .004; Table 3 ).
At visits under STC, median reported treatment duration was 347 days of past STC use (IQR, 90-750), with a P value <.10 (Supplementary Table 1 ). At 62/104 of visits with clinical remission (59.6%), patients reported long-term use of STC (!1 year), whereas this proportion was significantly lower for visits with no such remission (82/231, 35.5%; P < .001). However, in a multivariate model only age at disease onset and absence of PPI treatment remained significant. Patients without clinical remission despite steroid treatment were more likely to be treated with PPI. For prediction of endoscopic and histological remission, see Supplementary  Tables 2 and 3 . Longer STC intake and a negative family history of EoE were independent positive predictive factors for achieving complete remission at a given visit (2.02 [1.12-3 .64] and OR, 5.06 [1.53-16 .75], respectively; Table 2 ). During visits of patients in complete remission, higher proportions of long-term STC use and 
Per-Patient Data for Maintenance of Histologic Remission
To further investigate the effect of low-dose STC on maintenance of disease remission, we analyzed all patients who achieved histologic remission at 1 of their follow-up visits and computed Kaplan-Meier curves for time to histologic relapse. Patients were stratified into STC treatment (defined as under STC treatment at at least 1 of the following 2 visits) vs no such STC treatment. Seventy-four patients were identified with achievement of histologic remission in the follow-up (who were under STC treatment at the time of histologic remission) and at least 1 second follow-up endoscopy. Time to histologic relapse was significantly longer in the STC group 
Clinical Activity Despite Endoscopic and Histologic Remission
During the course of 120 visits (120/182, 65.9%; 1.8 years [IQR, 0.9-3.5] after enrollment), patients presented with EoE-attributed symptoms despite being in endoscopic and histologic disease remission. When compared with visits of patients in complete remission (n ¼ 62), visits of patients in endoscopic and histologic remission but ongoing disease activity (n ¼ 120) were more likely to be associated with less frequent treatment with STC at the time of follow-up visit (62.3% vs 90%, P < .001), shorter STC treatment duration (18 vs 403 days, P < .001) corresponding to a lower number of cumulative STC doses (120 vs 863, multiples of 0.25 mg, P < .001), higher number of strictures (36.5% vs 6.8%, P < .001), and endoscopic fibrotic features (59.1% vs 29.1%, P < .001). No differences between the 2 groups were observed when gender, atopic history, age at disease onset, and diagnostic delay were examined. In a multivariate analysis, lack of STC treatment (OR, 7 Table 4 ).
Safety Concerns Associated With Swallowed Topical Corticosteroid Use
In biopsy samples obtained during 310 visits for which past STC use was reported (2.0 years [IQR, 0.7-4.5] after enrollment, 26 visits without histologic evaluation), no dysplasia and no mucosal atrophy were detected. Histologically and endoscopically confirmed, symptomatic esophageal candidiasis warranting antifungal treatment was found at 9/336 visits under STC (2.7%).
Discussion
Swallowed topical corticosteroids have been demonstrated to reliably bring active EoE into clinical, endoscopic, and histologic remission. In contrast, data on long-term management and maintenance of remission are sparse. In this study, we comprehensively analyzed our Swiss EoE cohort to obtain an overview of effectiveness and safety of medical maintenance treatment in adult EoE patients.
The most important finding of our analysis is that STCs are more effective than no treatment in long-term EoE management. When follow-up visits were performed with ongoing medication use, the proportion of remission was 16.1%, whereas at visits during periods without STC ("drug-holidays"), this proportion was significantly lower (1.3%). This is a strong argument that after successful induction therapy, EoE patients should be considered for maintenance treatment. However, despite these optimistic data, patients frequently reported periods without STC use; in fact, STCs were taken at only 40% of the visits. Adherence to treatment seems to be an important issue. However, the periods of medication abstinence are comparable with other longterm treatments of chronic gastrointestinal diseases such as inflammatory bowel disease. 11 With a significant benefit from STCs over no treatment but high proportions of patient-initiated medication cessation, we advocate for a close monitoring of STC-treated patients including visits more often than once a year. Upcoming tools for assessment of histologic disease activity such as the Cytosponge or esophageal string test might facilitate more comprehensive follow-up in the future. 12, 13 Maintenance remission proportions are much lower than those seen after short-term induction treatment, leaving considerable room for improvement. Complete remission was only seen in 7.6% of 819 analyzed visits. The high proportions of ongoing disease activity, whether clinical, endoscopic, or histologic, shed light on the chronic nature of EoE and question the STC doses currently used in long-term management.
14 Dose-finding trials with higher STC doses are definitely needed. Compared with the conducted maintenance trial, with remission proportions of 64% (clinical) and 35% (histologic) in the adult population, clinical and complete remission proportions at visits with patient STC treatment (31% and 16.1%) were considerably lower in our study. 4 This might be due to the following reasons: (1) recall period for symptoms was longer in our study compared with the 1-week recall in the maintenance trial, (2) patients in the maintenance trial had closer follow-up visits (every 3 months) and more frequent assessment of their symptoms (every 1 week), whereas our study represents real-life conditions, and (3) followup was considerably longer in our study. Compared with our previously published deep remission study, proportions of complete remission (clinical, endoscopic, and histologic remission) were higher (16.1% at visits under STC treatment vs 9.4%), which is most probably due to the less stringent histologic definition than that used to define deep remission. 6 Despite these low maintenance remission proportions, longer duration of steroid treatment and higher cumulative doses were associated with higher proportions of complete remission compared with shorter treatment duration and lower doses. In fact, treatment for more than 1 year was an independent positive predictor for achievement of complete remission. When 4 classes of cumulative STC doses and treatment duration were compared, significant associations between complete remission and higher doses and longer duration of STCs were found. This is consistent with our previous data showing increasing, albeit modestly, rates of deep remission over time and lower rates of bolus impactions with higher frequency of STC intake. 5, 6 However, in the latter study we reported on adherence rather than exact duration and cumulative doses of treatment. Now we were able to show associations between treatment duration and doses and treatment outcome in a follow-up maintenance study. Interestingly, this association was only seen between treatment duration and complete remission and partially clinical remission, but not with endoscopic and histologic remission. It has yet to be determined whether this is the result of STC dose accumulation or more due to partial disease regression and therefore more treatable disease over time. Treating physicians and some patients might anticipate a longer course of low-dose STC maintenance to be effective. It remains unclear why a small subset of patients achieved endoscopic and histologic disease remission without STC treatment. We cannot rule out that some patients adhered to self-initiated dietary restrictions or under-reported STC use. On the basis of our previous study, ongoing disease remission without any treatment is very unlikely. 6 It is well-established that long-term use of corticosteroids poses risk for side effects. For instance, the administration of topical corticosteroids to the skin results in epithelial atrophy and disruption of epithelial integrity. 7, 8 Because the skin and the esophagus share many similarities regarding their histomorphologic structure, this potential side effect requires careful exploration because it may further facilitate antigen and fungal entry. In EoE, STCs in the applied dose of 0.25 mg twice daily appear to be safe and well-tolerated. Esophageal candida infections occur in a negligible proportion. In addition, our finding that no single case of mucosal atrophy or dysplasia was detected is reassuring. A dose of 0.25 mg twice daily, even in the long-term, is not harmful to the esophageal epithelial layer. This is consistent with our previous study, 6 but the biopsy number examined for the purposes of this study is considerably higher.
Because PPI responsiveness was an exclusion criterion, our study does not account for PPI-responsive EoE. However, this reflected the state of the art when the treatment concept was launched. PPI-responsive EoE and PPI as treatment for EoE have been included in the guidelines only very recently. 15 A clear limitation of this study is that the applied dose of STCs was most probably too low to achieve adequate drug levels in the esophageal mucosa. Thus, the high proportion of refractory cases most likely resulted from inadequate dosing. This is supported by our finding that higher cumulative doses of STCs are associated with a higher probability of disease remission. This apparently suboptimal dose was chosen because side effects were an important concern when determining the therapeutic dose to be used. Furthermore, 0.25 mg twice daily had shown a benefit over placebo in the only maintenance trial conducted in adults so far. 4 Because our concept with low-dose STCs is rigorously applied in our EoE cohort, a comparison with patients with higher maintenance doses was not possible but would be of particular interest in the future. Further limitations were the use of a non-validated symptom score, the reliance on patient-reported STC intake, and the considerable amount of missing data, which could have biased our results. Because almost all patients were treated with fluticasone, stratification by STC compound was not feasible.
In conclusion, EoE patients benefit from long-term treatment with STCs. This regimen has an excellent safety profile and the potential to alter the course of the disease. Of note, our data show that longer treatment and higher cumulative doses of STC are associated with higher proportions of disease remission. On the basis of these data, we advocate for indefinite long-term EoE treatment with STCs. Because patients rarely achieved complete remission with the STC doses used for the purposes of their clinical care, prospective long-term trials comparing different doses are needed in the future.
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Supplementary Methods
Inclusion Criteria for the Swiss EoE Database
Briefly, patients with active disease based on presence of typical EoE-associated symptoms, endoscopic features, and esophageal eosinophilia, defined as a peak count !15 eosinophils per hpf, were included. Patients were excluded if other diseases associated with esophageal eosinophilia were present. Underlying gastroesophageal reflux disease (GERD) was excluded on the basis of any one of the following: lack of typical symptoms, absence of hiatal hernia and signs of reflux esophagitis, non-response to PPI trial, or a positive 24-hour pH monitoring study (optional). Patients with persistent dysphagia and eosinophil inflammation, whose symptoms and signs of gastrointestinal reflux disease resolved after PPI treatment, were considered to have EoE and concomitant GERD and were not excluded from the SEED.
Therapeutic Concept of Maintenance Treatment With Swallowed Topical Corticosteroid
On the basis of our clinical experience and the findings of a maintenance treatment study, the following long-term concept was developed, and patients of the Swiss EoE Clinic have been treated according to the following principles:
Clinically and histologically active EoE was considered to be a clear indication for treatment; STC (fluticasone or budesonide) was used as first-line treatment for induction and maintenance of EoE remission.
The following treatment schedule was used. Induction treatment with fluticasone or budesonide at the dose of 1.0 mg twice daily (2.0 mg per day) was administered until clinical response (defined as 50%-70% reduction from baseline symptoms on a 10-point scale [non-validated symptom assessment]) was achieved (usually after 2-4 weeks of treatment); a maintenance treatment with fluticasone or budesonide at the dose of 0.25 mg twice daily (0.5 mg per day) followed.
Clinical, endoscopic, and histologic examination was performed once a year. During each visit the patients were asked about the presence and the severity of EoEand GERD-related symptoms, their eating habits, and their treatment regimen (cumulative dose and duration of treatment). Endoscopic findings were described in detail in a written report and documented with pictures. Four biopsies were taken from both the proximal and distal esophagus (total of 8 biopsies). As previously described, distal was defined as the section of the esophagus 5 cm above the gastroesophageal junction, whereas proximal was defined as the section spanning the top half of the esophagus. All biopsies were examined by an EoE reference pathologist (C.B.) or pathologist under his supervision. For the histologic examination, 4-mm sections were cut from the paraffin blocks. They were stained with H&E and van Gieson stains. In all cases, a standard pathology microscope (Zeiss Axiophot, Plan-Neofluar 40; Carl Zeiss, Oberkuchen, Germany; ocular magnification Â10, area of microscopic field 0.3072 mm 2 ) was used. At least 10 sections of each esophageal biopsy sample were examined, and the peak eosinophil count was reported.
As long as a disease activity was documented clinically, endoscopically, and/or histologically, the treatment with STC was continued for another year.
In case of deteriorating clinical, endoscopic, and/or histologic disease activity, patients underwent a second induction treatment for a period of 2-4 weeks.
Type of Swallowed Topical Corticosteroid and Drug Formulations
At our Swiss EoE Clinic, 2 STC formulations are prescribed for long-term maintenance treatment: (1) fluticasone powder from a metered-dose inhaler for asthma (one blister containing 0.25 mg fluticasone applied orally and swallowed twice a day); and (2) budesonide respules dissolved in syrup with a sucrose concentration of 64% (1 mL syrup ¼ .03 mg budesonide, swallowed at a dose of 0.25 mg twice daily). For practical reasons because syrup needs to be individually prepared by a pharmacy, whereas fluticasone inhalers are readily available, fluticasone is the treatment of choice for most of the patients.
Additional Statistical Analyses
For all statistical analyses, IBM SPSS software (version 22.0.0; 2013 SPSS Science, Chicago, IL) was used. Data distribution was analyzed by using Normal-QQ-Plots. Results of quantitative data are presented as either mean AE standard deviation (for normally distributed data) or median plus IQR in case of nonnormal distribution. Categorical data are summarized as the percentage of the group total. Differences in quantitative data distributions between 2 groups were assessed by using the unpaired Student t test (for continuous variables with normal distribution) and the Mann-Whitney-Wilcoxon test (for non-parametric data or continuous, but non-normally distributed data). Comparison between categorical data was performed by using c 2 test. Multivariate logistic regression was performed by first taking into account all covariates with univariate P value <.1, removing insignificant covariates, and then adding remaining covariates one by one, checking the model for significance and consistency. , and presence of allergic conditions (coded as yes or no). To evaluate the factors that might be associated with ongoing clinical activity despite endoscopic, histologic remission (ongoing symptoms as dependent variable), we also analyzed the following co-variables: strictures (coded as present or absent), endoscopic fibrotic signs (coded as present or absent), and prior endoscopic dilation (within 1 year before the examined visit, coded as yes or no). The linear-by-linear association test for trend was used to assess the association between duration of STC treatment (<100 days, 100 to <200 days, 200-300 days, and >300 days) and frequency of disease remission and to assess the association between cumulative doses of steroids (<200, 200 to <400, 400-600, >600 Â 0.25 mg) and disease remission. For the purpose of this study, a P value <.05 was considered statistically significant. 
